Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ASO treated adult Shank2 KO mice phosphoproteome

ABSTRACT: Decreased NMDA receptor function is a central mechanism implicated in various brain disorders, and extensive efforts to modulate NMDAR activity have been devoted in various therapeutic settings. We have previously established Slc6a20a as a novel glycine transporter, and using an antisense oligonucleotide ASO against Slc6a20a, we sought to modulate NMDAR function in well-established models of psychiatric disorders Shank2 and Shank3 mutant mice.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Junyeop Roh

LAB HEAD: Eunjoon Kim

PROVIDER: PXD061254 | Pride | 2026-04-24

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20220506_uniprot-proteome_UP000000589.fasta	Fasta
	BRI_E-02_DDA_20230414_IBS-shank2_TIS_PHO-TMT16_S1-FN1.raw	Raw
	BRI_E-02_DDA_20230414_IBS-shank2_TIS_PHO-TMT16_S1-FN10.raw	Raw
	BRI_E-02_DDA_20230414_IBS-shank2_TIS_PHO-TMT16_S1-FN11.raw	Raw
	BRI_E-02_DDA_20230414_IBS-shank2_TIS_PHO-TMT16_S1-FN12.raw	Raw

Items per page:

1 - 5 of 15

Similar Datasets

ASO-treated Shank3 HT mice proteome

Project description:Decreased NMDA receptor function is a central mechanism implicated in various brain disorders, and extensive efforts to modulate NMDAR activity have been devoted in various therapeutic settings. We have previously established Slc6a20a as a novel glycine transporter, and using an antisense oligonucleotide ASO against Slc6a20a, we sought to modulate NMDAR function in well-established models of psychiatric disorders Shank2 and Shank3 mutant mice.

2026-04-24 | PXD061255 | Pride

ASO-treated Shank2 KO mice total proteomic data

2026-04-24 | PXD061252 | Pride

ASO-treated Shank3 KO mice phosphoproteome

2026-04-24 | PXD061261 | Pride

ASO-treated Shank3 HT mice phosphoproteome

2026-04-24 | PXD061258 | Pride

Transcriptome analysis of memantine-treated Shank2 wild-type and knock-out mice

Project description:Shank2 is an excitatory postsynaptic scaffolding protein strongly implicated in autism spectrum disorders (ASD). Shank2-mutant mice with a homozygous deletion of exons 6 and 7 show decreased NMDA receptor (NMDAR) functions and autistic-like behaviors in juvenile (~postnatal day or P21) and adult (> P56) stages that are rescued by NMDAR activation. These mice, however, show an opposite change increased NMDAR functions—at ~P14, and NMDAR suppression by early and chronic memantine treatment during P7–21 prevents NMDAR hypofunction and autistic-like behaviors at juvenile (~P21) and adult (~P56) stages. To explore molecular mechanisms underlying the long-lasting effects of early memantine treatment, we performed RNA-Seq analysis of forebrains from wild-type and Shank2-mutant mice early and chronically treated with vehicle or memantine. Memantine-treated Shank2-mutant mice showed upregulations of chromatin-related genes and downregulations of mitochondria- and ribosome-related genes. In addition, vehicle-treated Shank2-mutant mice showed transcriptomic patterns that are largely opposite to those observed in ASD, as supported by the expression patterns of ASD-risk/related genes and cell-type-specific genes. These patterns, likely representing compensatory changes, were weakened by early memantine treatment. These results suggest that early chronic memantine treatment in Shank2-mutant mice alters chromatin- and mitochondria/ribosome-related gene expressions and weakens anti-ASD transcriptomic patterns.

2021-10-06 | GSE171931 | GEO

Comparison of DEG between memantine-, vehicle-treated and naive Shank2 wild-type and knock-out mice

Project description:Autism spectrum disorders (ASDs) are thought to involve diverse neurodevelopmental dysregulations that lead to visible symptoms at early stages of life. Many ASD-related mechanisms suggested by animal studies are supported by demonstrated improvement in autistic-like phenotypes in adult animals following experimental reversal of dysregulated mechanisms. However, whether such mechanisms also act at earlier stages to play important roles in the development of autistic-like phenotypes is unclear. Here, we show that early correction of a dysregulated mechanism in young mice prevents manifestation of autistic-like phenotypes in adult mice. Shank2–/– mice, known to display N-methyl-D-aspartate receptor (NMDAR) hypofunction and autistic-like behaviors at post-weaning stages after postnatal day 21 (P21), show the opposite synaptic phenotype—NMDAR hyperfunction—at an earlier pre-weaning stage (~P14). Moreover, this NMDAR hyperfunction at P14 is rapidly shifted to NMDAR hypofunction after weaning (~P24). Chronic suppression of the early NMDAR hyperfunction in Shank2–/– mice by the NMDAR antagonist memantine before weaning (P7–21) prevents the NMDAR hypofunction and autistic-like behaviors from manifesting at later stages (~P28 and P56). In addition, early memantine treatment of Shank2–/– mice substantially alters transcription of numerous genes, driving gene expression patterns in a direction largely opposite that observed in drug-untreated Shank2–/– mice, which, interestingly, mimic those observed in autistic individuals. These results suggest that early NMDAR hyperfunction in Shank2–/– mice leads to late NMDAR hypofunction and autistic-like behaviors, and that early correction of NMDAR function has the long-lasting effect of preventing autistic-like phenotypes from developing at later stages. This SuperSeries is composed of the SubSeries listed below.

2021-04-20 | GSE97896 | GEO

Glycine-modulating Slc6a20a-ASO restores NMDA receptor function in SHANK2 and SHANK3-mutant mice and cortical organoids

Project description:Glycine-modulating Slc6a20a-ASO restores NMDA receptor function in SHANK2 and SHANK3-mutant mice and cortical organoids

| PRJNA1234530 | ENA

Whole brain transcriptome analysis of Shank2 knock-out mice

Project description:Autism spectrum disorders (ASDs) are thought to involve neurodevelopmental dysregulations that lead to visible symptoms at early stages of life. Many ASD-related mechanisms suggested by animal studies are supported by demonstrated improvement in autistic-like phenotypes in adult animals following experimental reversal of dysregulated mechanisms. However, whether such mechanisms also act at earlier stages to cause autistic-like phenotypes is unclear. Here, we show that early correction of a dysregulated mechanism in young mice prevents manifestation of autistic-like phenotypes in adult mice. Shank2–/– mice, known to display N-methyl-D-aspartate receptor (NMDAR) hypofunction and autistic-like behaviors at post-weaning stages after postnatal day 21 (P21), show the opposite synaptic phenotype–NMDAR hyperfunction–at an earlier pre-weaning stage (~P14). Moreover, this NMDAR hyperfunction at P14 is rapidly shifted to NMDAR hypofunction after weaning (~P24). Chronic suppression of the early NMDAR hyperfunction by the NMDAR antagonist memantine (P7?21) prevents the NMDAR hypofunction and autistic-like behaviors from manifesting at later stages (~P28 and P56). These results suggest that early NMDAR hyperfunction leads to late NMDAR hypofunction and autistic-like behaviors in Shank2–/– mice, and that early correction of NMDAR function has the long-lasting effect of preventing autistic-like phenotypes from developing at later stages.

2021-04-20 | GSE82066 | GEO

Brain transcriptome analysis of Slc6a20a heterozygous and homozygous mutant mice

Project description:SLC6A20A is a proline and glycine transporter known to regulate glycine homeostasis and NMDA receptor (NMDAR) function in the brain. A previous study on Slc6a20a-haploinsufficient mice reported increases in ambient glycine levels and NMDA receptor-mediated synaptic transmission in the brain, but whether Slc6a20a deficiency leads to disease-related behavioral deficits in mice remains unknown. Here, we report that Slc6a20a heterozygous and homozygous mutant mice display gene dosage-dependent behavioral phenotypes in locomotor, repetitive behavioral, and fear memory domains. In addition, Slc6a20a heterozygous and homozygous mutant brains showed transcriptomic changes in synapse, ribosome, and mitochondria-related genes as well as autism, epilepsy, and neuron-related genes. These results suggest that Slc6a20a deletion leads to gene dosage-dependent behavioral deficits in mice and transcriptomic changes in genes associated with synapse, ribosome, mitochondria, ASD, epilepsy, and neurons

2022-02-07 | GSE193387 | GEO

Amelioration of autism-like social deficits by targeting histone methyltransferases EHMT1/2 in Shank3-deficient mice

Project description:Many of the genes disrupted in autism are identified as histone-modifying enzymes and chromatin remodelers, most prominently those that mediate histone methylation/demethylation. However, the role of histone methylation enzymes in the pathophysiology and treatment of autism remains unknown. To address this, we used mouse models of haploinsufficiency of the Shank3 gene (a highly penetrant monogenic autism risk factor), which exhibits prominent autism-like social deficits. We found that histone methyltransferases EHMT1 and EHMT2, as well as histone lysine 9 dimethylation (specifically catalyzed by EHMT1/2), were selectively increased in the prefrontal cortex (PFC) of Shank3-deficient mice and autistic human postmortem brains. Treatment with the EHMT1/2 inhibitor UNC0642 or knockdown of EHMT1/2 in PFC induced a robust rescue of autism-like social deficits in Shank3-deficient mice, and restored NMDAR-mediated synaptic function. Activityregulated cytoskeleton-associated protein (Arc) was identified as one of the causal factors underlying the rescuing effects of UNC0642 on NMDAR function and social behaviors in Shank3-deficient mice. UNC0642 treatment also restored a large set of genes involved in neural signaling in PFC of Shank3-deficient mice. These results suggest that targeting histone methylation enzymes to adjust gene expression and ameliorate synaptic defects could be a potential therapeutic strategy for autism.

2020-07-29 | GSE155291 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data